Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP070
MIFTS: 38

Hyperpituitarism

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hyperpituitarism

About this section

MalaCards integrated aliases for Hyperpituitarism:

Name: Hyperpituitarism 12 44 15 73

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2444
MeSH 44 D006964
SNOMED-CT 68 10649000
UMLS 73 C0020506
Sources

Summaries for Hyperpituitarism

About this section
MalaCards based summary : Hyperpituitarism is related to hyperthyroidism and hypopituitarism. An important gene associated with Hyperpituitarism is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are TGF-Beta Pathway and Peptide ligand-binding receptors. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and kidney, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : 76 Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones, it typically... more...

Sources

Related Diseases for Hyperpituitarism

About this section

Diseases related to Hyperpituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 hyperthyroidism 29.7 GH1 INS PRL SST TRH
2 hypopituitarism 29.0 PRL POMC INS IGFBP3 IGF1 GHRH
3 galactorrhea 10.2 PRL IGF1
4 glucagonoma 10.2 SST GHRH
5 prolactin producing pituitary tumor 10.2 SST PRL
6 pancreatic cholera 10.2 SST GHRH
7 bronchus adenoma 10.2 POMC SST
8 bronchial adenomas/carcinoids childhood 10.2 POMC SST
9 generalized resistance to thyroid hormone 10.2 TRH PRL
10 spinocerebellar degeneration 10.2 SST PRL
11 zollinger-ellison syndrome 10.2 SST GHRH
12 fasting hypoglycemia 10.2 POMC IGF1
13 fibrous dysplasia/mccune-albright syndrome 10.2 GH1 PRL
14 slipped capital femoral epiphysis 10.2 IGF1 IGFBP3
15 acth-secreting pituitary adenoma 10.2 PRL POMC
16 graves' disease 10.2
17 cone-rod dystrophy 12 10.2 IGF1 GH1
18 suprasellar meningioma 10.2 TRH POMC
19 diffuse idiopathic skeletal hyperostosis 10.2 IGFBP3 IGF1
20 abducens nerve disease 10.2 PRL POMC
21 fibromyalgia 10.2 IGF1 PRL
22 lymphocytic hypophysitis 10.1 POMC GH1
23 acid-labile subunit deficiency 10.1 IGFBP3 IGF1
24 carcinoid syndrome 10.1 GHRH IGF1 SST
25 diabetes insipidus, neurohypophyseal 10.1 PRL POMC
26 hypoadrenalism 10.1 POMC GH1
27 traumatic brain injury 10.1 IGF1 GH1
28 acidophil adenoma 10.1 IGF1 POMC SST
29 tetrahydrobiopterin deficiency 10.1 PRL GH1
30 ectopic cushing syndrome 10.1 SST POMC
31 premenstrual tension 10.1 PRL POMC
32 osteoporosis, juvenile 10.1 IGFBP3 IGF1
33 chiasmal syndrome 10.1 POMC PRL SST
34 pituitary carcinoma 10.1 POMC PRL SST
35 nelson syndrome 10.1 POMC PRL SST
36 adrenal cortex disease 10.1 POMC PRL SST
37 sella turcica neoplasm 10.1 GHRH POMC PRL
38 tuberculum sellae meningioma 10.1 GHRH POMC PRL
39 acromesomelic dysplasia, maroteaux type 10.1 IGF1 GHR
40 hormone producing pituitary cancer 10.1 AIP IGF1 SST
41 pituitary stalk interruption syndrome 10.1 GH1 PRL
42 mammographic density 10.0 IGF1 IGFBP3 PRL
43 amenorrhea 10.0 POMC PRL TRH
44 multiple endocrine neoplasia, type iv 10.0 AIP PRL
45 postural hypotension 10.0 SST INS
46 growth hormone secreting pituitary adenoma 10.0 AIP PRL SST
47 postgastrectomy syndrome 10.0 SST INS
48 duodenal somatostatinoma 10.0 SST INS
49 somatostatinoma 10.0 SST INS
50 noma 10.0 POMC INS

Graphical network of the top 20 diseases related to Hyperpituitarism:



Diseases related to Hyperpituitarism
Sources

Symptoms & Phenotypes for Hyperpituitarism

About this section

MGI Mouse Phenotypes related to Hyperpituitarism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.06 AIP GHR GHRH IGF1 IGFBP3 INS
2 growth/size/body region MP:0005378 10.02 AIP GHR GHRH IGF1 IGFBP3 INS
3 homeostasis/metabolism MP:0005376 10.02 AIP GHR GHRH IGF1 IGFBP3 INS
4 adipose tissue MP:0005375 9.83 GHR IGF1 IGFBP3 INS POMC
5 integument MP:0010771 9.8 AIP GHR IGF1 IGFBP3 INS POMC
6 liver/biliary system MP:0005370 9.7 AIP GHR GHRH IGFBP3 INS POMC
7 nervous system MP:0003631 9.56 GHR GHRH IGF1 INS POMC PRL
8 renal/urinary system MP:0005367 9.02 GHR IGF1 IGFBP3 INS POMC
Sources

Drugs & Therapeutics for Hyperpituitarism

About this section

Drugs for Hyperpituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
3
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
4 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
5
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83150-76-9 383414 6400441
6
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
7
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
8
Mecasermin Approved, Investigational Phase 4,Phase 3,Not Applicable 68562-41-4
9
Quinagolide Approved, Investigational Phase 4 97805-50-0, 87056-78-8 105105
10
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Metformin Approved Phase 4 657-24-9 14219 4091
13
Zinc Approved, Investigational Phase 4 7440-66-6
14 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
15
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
16
Polyestradiol phosphate Approved Phase 4 28014-46-2
17
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
18 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
20 Dopamine D2 Receptor Antagonists Phase 4
21 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Serotonin Agents Phase 4,Phase 3,Not Applicable
24 Serotonin Antagonists Phase 4,Phase 3,Not Applicable
25 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Serotonin 5-HT2 Receptor Antagonists Phase 4
27 Paliperidone Palmitate Phase 4
28 Dopamine Antagonists Phase 4,Phase 3,Not Applicable
29 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Mitogens Phase 4,Phase 3,Phase 2,Not Applicable
32 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable
36 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 insulin Phase 4,Phase 3,Phase 2,Not Applicable
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Complement Factor I Phase 4,Phase 3
40 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2
41 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
42 Protective Agents Phase 4,Phase 1,Phase 2
43 Incretins Phase 4
44 Liver Extracts Phase 4
45 Autonomic Agents Phase 4,Phase 2,Phase 1
46 Sympathomimetics Phase 4,Phase 1,Phase 2
47 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
48 Cardiotonic Agents Phase 4,Phase 1,Phase 2
49 Dipeptidyl-Peptidase IV Inhibitors Phase 4
50 Sitagliptin Phosphate Phase 4

Interventional clinical trials:

(show top 50) (show all 211)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
2 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
3 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
4 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
5 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
6 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
7 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
8 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
9 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
10 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
11 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
12 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
13 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
14 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
15 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
16 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
17 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
18 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
19 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
20 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
21 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
22 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
23 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
24 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
25 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
26 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
27 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
28 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
29 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
30 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
31 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
32 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
33 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
34 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
35 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
36 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Phase 3 Calcium and Vitamin D
37 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
38 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
39 Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Completed NCT02354508 Phase 3 Pasireotide LAR
40 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
41 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
42 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
43 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
44 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
45 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
46 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
47 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
48 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
49 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
50 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant

Search NIH Clinical Center for Hyperpituitarism

Cochrane evidence based reviews: hyperpituitarism

Sources

Genetic Tests for Hyperpituitarism

About this section
Sources

Anatomical Context for Hyperpituitarism

About this section

MalaCards organs/tissues related to Hyperpituitarism:

41
Pituitary, Brain, Kidney, Ovary, Pancreas, Thyroid, Cortex
Sources

Publications for Hyperpituitarism

About this section

Articles related to Hyperpituitarism:

# Title Authors Year
1
Hyperpituitarism ( 29489207 )
2018
2
Congenital hyperpituitarism of hypothalamic origin: a new diencephalic syndrome with endocrine manifestations. ( 14444640 )
1959
3
Psychological findings in a case of von Recklinghausen's disease and hyperpituitarism. ( 13367234 )
1956
4
Further evidence that hyperthyroidism (Graves' disease) is not hyperpituitarism: effects of triiodothyronine and sodium iodide. ( 14367487 )
1955
5
Graves' disease: hyperthyroidism or hyperpituitarism. ( 13022743 )
1952
6
Creatine-creatinine metabolism in adult and juvenile hyperpituitarism. ( 18877070 )
1948
7
Hyperpituitarism and Hypopituitarism. ( 19312151 )
1940
8
Thyrotoxicosis with Unilateral Exophthalmos, Hyperpituitarism, and Infantile Hemiplegia. ( 19990197 )
1935
9
Case of Hyperpituitarism. ( 19984234 )
1925
Sources

Variations for Hyperpituitarism

About this section
Sources

Expression for Hyperpituitarism

About this section
Search GEO for disease gene expression data for Hyperpituitarism.
Sources

Pathways for Hyperpituitarism

About this section

Pathways related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
TGF-Beta Pathway 64
Show member pathways
 13.17 GH1 GHR GHRH IGF1 INS PRL
2
Peptide ligand-binding receptors 66
Show member pathways
 12.97 GH1 GHR GHRH POMC PRL SST
3
PI3K-Akt signaling pathway 37
Show member pathways
 12.61 GH1 GHR IGF1 INS PRL
4
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.49 GH1 GHR IGF1 IGFBP3 INS
5
Adipogenesis 1
11.73 GH1 IGF1 INS
6
Senescence and Autophagy in Cancer 1
11.61 IGF1 IGFBP3 INS
7
Peptide hormone metabolism 66
Show member pathways
 11.52 GH1 IGF1 INS POMC
8
Endochondral Ossification 1
11.25 GH1 GHR IGF1
9
Aldosterone-regulated sodium reabsorption 37
11.08 IGF1 INS
10
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 10.97 POMC TRH
11
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
10.8 IGF1 IGFBP3
12
Growth hormone receptor signaling 66
Show member pathways
 10.41 GH1 GHR PRL
Sources

GO Terms for Hyperpituitarism

About this section

Cellular components related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 GH1 GHR GHRH IGF1 IGFBP3 INS
2 secretory granule GO:0030141 9.58 POMC PRL TRH
3 insulin-like growth factor ternary complex GO:0042567 9.37 IGF1 IGFBP3
4 endosome lumen GO:0031904 9.33 GH1 INS PRL
5 insulin-like growth factor binding protein complex GO:0016942 9.32 IGF1 IGFBP3
6 extracellular region GO:0005576 9.32 GH1 GHR GHRH IGF1 IGFBP3 INS
7 growth hormone receptor complex GO:0070195 9.26 GH1 GHR

Biological processes related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.9 GHRH IGF1 INS PRL
2 cellular protein metabolic process GO:0044267 9.76 IGF1 IGFBP3 INS PRL
3 positive regulation of MAPK cascade GO:0043410 9.73 IGF1 IGFBP3 INS
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 GH1 GHR IGF1
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 GH1 IGF1 INS
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 GH1 GHR IGF1
7 cell-cell signaling GO:0007267 9.65 GHRH INS POMC SST TRH
8 activation of protein kinase B activity GO:0032148 9.62 IGF1 INS
9 positive regulation of glucose import GO:0046326 9.61 IGF1 INS
10 positive regulation of mitotic nuclear division GO:0045840 9.59 IGF1 INS
11 response to food GO:0032094 9.58 GHR GHRH
12 positive regulation of glycolytic process GO:0045821 9.58 IGF1 INS
13 positive regulation of multicellular organism growth GO:0040018 9.58 GH1 GHR GHRH
14 positive regulation of glycogen biosynthetic process GO:0045725 9.57 IGF1 INS
15 insulin-like growth factor receptor signaling pathway GO:0048009 9.55 GHR IGF1
16 growth hormone receptor signaling pathway GO:0060396 9.54 GH1 GHR
17 regulation of multicellular organism growth GO:0040014 9.54 GHR IGF1 PRL
18 negative regulation of feeding behavior GO:2000252 9.51 INS TRH
19 positive regulation of JAK-STAT cascade GO:0046427 9.5 GH1 GHR PRL
20 positive regulation of lactation GO:1903489 9.43 GHRH PRL
21 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.33 GH1 GHR PRL
22 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GH1 GHRH IGF1 IGFBP3
23 regulation of signaling receptor activity GO:0010469 9.23 GH1 GHRH IGF1 INS POMC PRL
24 G protein-coupled receptor signaling pathway GO:0007186 10 GHRH INS POMC SST TRH

Molecular functions related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.26 IGF1 INS
2 hormone activity GO:0005179 9.23 GH1 GHRH IGF1 INS POMC PRL
3 insulin-like growth factor receptor binding GO:0005159 9.16 IGF1 INS
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL
Sources

Sources for Hyperpituitarism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....